» Articles » PMID: 12960187

Imaging Proliferation in Lung Tumors with PET: 18F-FLT Versus 18F-FDG

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2003 Sep 10
PMID 12960187
Citations 123
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Recently, the thymidine analog 3'-deoxy-3'-(18)F-fluorothymidine (FLT) was suggested for imaging tumoral proliferation. In this prospective study, we examined whether (18)F-FLT better determines proliferative activity in newly diagnosed lung nodules than does (18)F-FDG.

Methods: Twenty-six patients with pulmonary nodules on chest CT were examined with PET and the tracers (18)F-FDG and (18)F-FLT. Tumoral uptake was determined by calculation of standardized uptake value (SUV). Within 2 wk, patients underwent resective surgery or had core biopsy. Proliferative activity was estimated by counting nuclei stained with the Ki-67-specific monoclonal antibody MIB-1 per total number of nuclei in representative tissue specimens. The correlation between the percentage of proliferating cells and the SUVs for (18)F-FLT and (18)F-FDG was determined using linear regression analysis.

Results: Eighteen patients had malignant tumors (13 with non-small cell lung cancer [NSCLC], 1 with small cell lung cancer, and 4 with pulmonary metastases from extrapulmonary tumors); 8 had benign lesions. In all visible lesions, mean (18)F-FDG uptake was 4.1 (median, 4.4; SD, 3.0; range, 1.0-10.6), and mean (18)F-FLT uptake was 1.8 (median, 1.2; SD, 2.0; range, 0.8-6.4). Statistical analysis revealed a significantly higher uptake of (18)F-FDG than of (18)F-FLT (Mann-Whitney U test, P < 0.05). (18)F-FLT SUV correlated better with proliferation index (P < 0.0001; r = 0.92) than did (18)F-FDG SUV (P < 0.001; r = 0.59). With the exception of 1 carcinoma in situ, all malignant tumors showed increased (18)F-FDG PET uptake. (18)F-FLT PET was false-negative in the carcinoma in situ, in another NSCLC with a low proliferation index, and in a patient with lung metastases from colorectal cancer. Increased (18)F-FLT uptake was related exclusively to malignant tumors. By contrast, (18)F-FDG PET was false-positive in 4 of 8 patients with benign lesions.

Conclusion: (18)F-FLT uptake correlates better with proliferation of lung tumors than does uptake of (18)F-FDG and might be more useful as a selective biomarker for tumor proliferation.

Citing Articles

Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective.

Xiao Y, Li Y, Zhao H Mol Cancer. 2024; 23(1):202.

PMID: 39294747 PMC: 11409752. DOI: 10.1186/s12943-024-02113-9.


Emerging Role of [F]FLT PET/CT in Lymphoid Malignancies: A Review of Clinical Results.

Nappi A, Santo G, Jonghi-Lavarini L, Miceli A, Lazzarato A, La Torre F Hematol Rep. 2024; 16(1):32-41.

PMID: 38247994 PMC: 10801569. DOI: 10.3390/hematolrep16010004.


Radiomic analysis will add differential diagnostic value of benign and malignant pulmonary nodules: a hybrid imaging study based on [F]FDG and [F]FLT PET/CT.

Ning J, Li C, Yu P, Cui J, Xu X, Jia Y Insights Imaging. 2023; 14(1):197.

PMID: 37980611 PMC: 10657912. DOI: 10.1186/s13244-023-01530-6.


High efficacy of particle beam therapies against tumors under hypoxia and prediction of the early stage treatment effect using 3'-deoxy-3'-[F]fluorothymidine positron emission tomography.

Makino A, Kume K, Mori T, Tsujikawa T, Asai T, Okazawa H Ann Nucl Med. 2023; 38(2):112-119.

PMID: 37856073 PMC: 10822821. DOI: 10.1007/s12149-023-01877-2.


3'-Deoxy-3'-(18F) Fluorothymidine Positron Emission Tomography/Computed Tomography in Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Pilot Study.

Lewis S, Chan M, Weiss J, Raziee H, Driscoll B, Bezjak A Adv Radiat Oncol. 2022; 7(6):101037.

PMID: 36420186 PMC: 9677203. DOI: 10.1016/j.adro.2022.101037.